Anti-TIMMDC1/C3orf1 antibody [EPR11807]

4 product images

• 

  Immunoprecipitation - Anti-TIMMDC1/C3orf1 antibody [EPR11807] (ab171978)

  Western blot analysis on immunoprecipitation pellet from A375 cell lysate labeling TIMMDC1/C3orf1 with ab171978 at 1/10 dilution.

  All lanes: Immunoprecipitation - Anti-TIMMDC1/C3orf1 antibody [EPR11807] (ab171978)

  Predicted band size: 32 kDa

• 

  Western blot - Anti-TIMMDC1/C3orf1 antibody [EPR11807] (ab171978)

  All lanes: Western blot - Anti-TIMMDC1/C3orf1 antibody [EPR11807] (ab171978) at 1/10000 dilution

  Lane 1: THP1 cell lysate at 10 µg

  Lane 2: U937 (Human histiocytic lymphoma cell line) cell lysate at 10 µg

  Lane 3: A375 cell lysate at 10 µg

  Lane 4: HepG2 cell lysate at 10 µg

  Lane 5: Fetal heart tissue lysate at 10 µg

  Predicted band size: 32 kDa

• 

  Immunocytochemistry/ Immunofluorescence - Anti-TIMMDC1/C3orf1 antibody [EPR11807] (ab171978)

  Immunofluorescent analysis of HepG2 cells labeling TIMMDC1/C3orf1 with ab171978 at 1/100 dilution (red). DAPI nuclear staining (blue).

• 

  Image collected and cropped by CiteAb under a CC-BY license from the publication

  Western blot - Anti-TIMMDC1/C3orf1 antibody [EPR11807] (ab171978)

  TIMMDC1/C3orf1 western blot using anti-TIMMDC1/C3orf1 antibody [EPR11807] ab171978. Publication image and figure legend from Kremer, L. S., Bader, D. M., et al., 2017, Nat Commun, PubMed 28604674.

  
  

  ab171978 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab171978 please see the product overview.

  RNA aberrant expression detection and validation.(a) Aberrantly expressed genes (Hochberg corrected P value<0.05 and |Z-score|>3) for each patient fibroblasts. (b) Gene-wise RNA expression volcano plot of nominal P values (−log10P value) against Z-scores of the patient #35791 compared against all other fibroblasts. Z-scores with absolute value >5 are plotted at ±5, respectively. (c) Same as (b) for patient #73804. (d) Sample-wise RNA expression is ranked for the genes TIMMDC1 (top) and MGST1 (bottom). Samples with aberrant expression for the corresponding gene are highlighted in red (#35791, #66744, and #73804). (e) Gene-wise comparison of RNA and protein fold changes of patient #35791 compared to the average across the fibroblast cell lines of all other patients. Subunits of the mitochondrial respiratory chain complex I are highlighted (red squares). Reliably detected proteins that were not detected in this sample are shown separately with their corresponding RNA fold changes (points below solid horizontal line). (f) Western blot of TIMMDC1, NDUFA13, NDUFB3 and NDUFB8 protein in three fibroblast cell lines without (#62346, #91324, NHDF) and three with a variant in TIMMDC1 (#35791, #66744 and #96687), and fibroblasts re-expressing TIMMDC1 (‘-T’) (#35791-T, #66744-T and #96687-T). UQCRC2 was used as loading control. CI, complex I subunit; CIII, complex III subunit; MW, molecular weight. (g) Blue native PAGE blot of the control fibroblasts re-expressing TIMMDC1 (NHDF-T), the control fibroblasts (NHDF), patient fibroblasts (#96687) and patient fibroblast re-expressing TIMMDC1 (#96687-T). Immunodecoration for complex I and complex III was performed using NDUFB8 and UQCRC2 antibodies, respectively. CI, complex I subunit; CIII, complex III subunit.